Blood and Marrow Transplantation & Cellular Therapy
World Class Expertise in Patient Care and Research
Message From the Chief
Welcome to the Blood and Marrow Transplantation & Cellular Therapy Division. We are a nationally recognized center of excellence, fully accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) and a proud member of the Blood and Marrow Transplant Clinical Trials Network of the National Cancer Institute.
Stanford Medicine’s Lori Muffly, MD and Matthew Frank, MD, PhD from Stanford Medicine in Stanford, CA, were recently featured on The Bloodline with LLS, the podcast by The Leukemia & Lymphoma Society (LLS) for patients and caregivers. In this episode, the doctors delve into what Minimal/Measurable Disease (MRD) is, which blood cancers testing is currently used on, and how we can utilize it to more accurately monitor patients and customize treatment. The doctors also share exciting possibilities on how MRD and other testing can benefit patients in the future.
The most exciting science typically happens when groups from different disciplines or with different points of views come together.
One of the SCI’s major missions is to promote the collaboration and interaction of its 400 faculty members and bring this expertise to the benefit of the patient.
One way to bring the powerful cellular immunity and antibody directed targeting together is to construct the chimeric antigen receptor (CAR) T-cells. In this strategy, the patient’s own T-cells are genetically engineered to produce a hybrid molecule (the CAR) on these killing cells.
In order to monitor disease after a curative treatment such as allogeneic transplant, pioneer works from Drs. David Miklos and Wen-Kai Weng have established the utility of high-throughput sequencing (HTS) of either B-cell receptor (BCR) or T-cell receptor (TCR) in monitoring minimal residual disease (MRD).
The development of normal lymphocytes is a well-orchestrated process, that begins in the bone marrow. This process involves a functional antigen receptor (B-cell receptor or T-cell receptor) and a dozen of intermediators, including adaptor proteins and kinases that form a network of signaling pathways inside the cells.
Since the establishment of Stanford BMT program in 1987, many aspects of the clinical practice have changed.
When Robin was first diagnosed with acute myeloid leukemia in December 2011, she knew that it would be a long journey for her fight against this cancer.
While the graft-versus-tumor effect provided by the donor graft can be very powerful in controlling the disease, disease relapse is still the primary reason that patients do not do well after an allogeneic transplantation.
While allogeneic transplantation can be life saving for patients with hematologic malignancies, or inherited disorders such as several forms of immuno-deficiency, the transplant-related side effects and complications remain the biggest hurdles.
When Kohler and Milstein developed hybridoma technology in 1975, a monoclonal antibody was thought to be the “Magic Bullet” to treat cancer since it can go directly to the targeted cancer cells.
When someone has mycosis fungoides, malignant cells in the blood travel to the skin, causing lesions that appear as an itchy rash.
While the role for the individual cell population of the donor graft is not fully understood after allogeneic transplant, recent works in the field have yielded some interesting observations which may lead to advances in clinical care.
Make a Gift
Our cutting-edge research is developing novel immunotherapy for cancer. Support the BMT Division by making a donation to our research fund.
In this interview, Dr. Miklos talks in-depth about CAR T-cell therapy, mantle cell lymphoma treatments, allogeneic transplants, and gives his thoughts on future therapies.
Cellular immunotherapy is a new way of treating cancer. Cellular immunotherapy is a breakthrough because it's a living therapy; the cells that are administered can last in patients for weeks, months, even years. SCI members Crystal Mackall, MD and David Miklos, MD, PhD opened the first ever clinical trial for a bi-specific (CD19xCD22) CAR-T cell.
In the News
DID YOU KNOW
Over 400 patients received bone marrow or stem cell transplants at Stanford last year.
Karl G. Blume, M.D. Memorial Lecture
The Karl G. Blume, MD Memorial Lectureship was established to honor Dr. Blume’s countless contributions to the field of blood and marrow transplantation, and to Stanford University and Stanford Hospital and Clinics. The lectureship is held the second Wednesday of each April at Stanford University’s Department of Medicine Grand Rounds.
Dr. Blume and his team conducted Stanford’s first successful Bone Marrow Transplant on November 2, 1987. Today the program provides transplants to over 300 adult patients a year, with over 5,000 patients receiving transplants during the past 30 years.
Read the Tribute to Dr. Blume here.